TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01880268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation therapy
Description: Standard rehabilitation therapy for patient with stroke includes 1 hour of physical therapy and 1 hour of occupational therapy
Study: NCT01590199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230
Study: NCT03269955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen/thrombin-coated collagen patch
Description: Tachosil® is cut in half and applied to the front and back of the pancreaticojejunostomy respectively, and fibrin glue is applied on it
Study: NCT02881359

Intervention type: DEVICE
Intervention: LifeSeal® Kit
Description: used as an adjunct to suture or staple line during standard surgical repair of the GI tract (anastomosis or linear) to provide re-inforcement and help reduce leaks.
Study: NCT01702415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Single dose, intravenous solution 5mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00681473

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation Therapy
Description: Once daily, Monday through Friday, for 6 weeks.
Study: NCT02681588

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Obstetric management
Description: Screening for gestational diabetes at 32 weeks of gestation, determination of fasting glucose during late pregnancy ; blood samples on arrival at the delivery room ; drawing blood from the umbilical cord after section; skinfold measurement of the newborn within 72 hours of life.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Obstetric management
Description: Screening for gestational diabetes at 32 weeks of gestation, determination of fasting glucose during late pregnancy ; blood samples on arrival at the delivery room ; drawing blood from the umbilical cord after section; skinfold measurement of the newborn within 72 hours of life.
Study: NCT02208973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-680
Description: 5, 10, 20, 40 and 60 mg of PBF-680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-680
Description: 5, 10, 20, 40 and 60 mg of PBF-680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-680
Description: 5, 10, 20, 40 and 60 mg of PBF-680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-680
Description: 5, 10, 20, 40 and 60 mg of PBF-680
Study: NCT06642779

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Biometry
Description: Axial length, anterior chamber depth and corneal keratometric values K1-K2. All these parameters were measured at the screening visit and at the month 3 follow-up visit, using the ARGOS® Biometer or the ANTERION® Cataract App
Study: NCT03791983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scalp Acupuncture
Description: Scalp acupuncture is a form of alternative medicine in which thin needles are inserted into the scalp. It is a key component of traditional Chinese medicine (TCM).

Intervention type: OTHER
Group type: OTHER
Intervention: Body Acupenture
Description: Acupuncture is a form of alternative medicine in which thin needles are inserted into the body. It is a key component of traditional Chinese medicine (TCM).
Study: NCT06642779

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Biometry
Description: Axial length, anterior chamber depth and corneal keratometric values K1-K2. All these parameters were measured at the screening visit and at the month 3 follow-up visit, using the ARGOS® Biometer or the ANTERION® Cataract App

Intervention type: DIAGNOSTIC_TEST
Intervention: Slit lamps / Fundoscopy / Biomicroscopy
Description: The fundus and other ocular structures, such as the cornea, anterior chamber, iris, pupil, crystalline lens / IOL alignment, corpus ciliare and choroid were examined at screening visit, on the day of the surgery, and at the follow up visits D1, M1, M3, M6, and M12, using the slit lamp binocular indirect ophthalmoscopy.
Study: NCT01670630

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sheathed speculum examination

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard speculum examination
Study: NCT04548999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (body weight \<75 kg) or 1800 mg (body weight ≥ 75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion Q24W.~During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered at a dose of 600 mg Q24W. The first dose of ocrelizumab will be administered as two 300 mg, IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion Q24W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihistamine
Description: Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
Study: NCT04420455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoximone
Description: Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval.
Study: NCT01024465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReShape Duo Balloon
Description: ReShape Duo Balloon
Study: NCT02208973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-680
Description: 5, 10, 20, 40 and 60 mg of PBF-680

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for the dose of 5, 10, 20 and 40 mg of PBF-680
Study: NCT03995550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 142397
Description: A compound in development by LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 142397
Description: A compound in development by LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 142397
Description: A compound in development by LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 142397
Description: A compound in development by LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 142397
Description: A compound in development by LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 142397
Description: A compound in development by LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 142397
Description: A compound in development by LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 142397
Description: A compound in development by LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 142397
Description: A compound in development by LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 142397
Description: A compound in development by LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 142397
Description: A compound in development by LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 142397
Description: A compound in development by LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 142397
Description: A compound in development by LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 142397
Description: A compound in development by LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04411173

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein
Description: Each condition (both rice and whey protein) match in color, flavor, and serving size.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein
Description: Each condition (both rice and whey protein) match in color, flavor, and serving size.
Study: NCT06642779

Intervention type: DIAGNOSTIC_TEST
Intervention: Slit lamps / Fundoscopy / Biomicroscopy
Description: The fundus and other ocular structures, such as the cornea, anterior chamber, iris, pupil, crystalline lens / IOL alignment, corpus ciliare and choroid were examined at screening visit, on the day of the surgery, and at the follow up visits D1, M1, M3, M6, and M12, using the slit lamp binocular indirect ophthalmoscopy.

Intervention type: DIAGNOSTIC_TEST
Intervention: UDVA
Description: Monocular and binocular Uncorrected Distance Visual Acuity (UDVA) was evaluated at all visits (preoperative, D1, M1, M3, M6 and M12), using the ETDRS chart.
Study: NCT03304821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Participants will self-administer 500 μg/day of GM-CSF, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of subcutaneous GM-CSF, three times per week for another 3 weeks and then will be followed for another 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will self-administer 500 μg/day of a placebo, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of a placebo administered subcutaneously, three times per week for another 3 weeks and then will be followed for another 3 months.
Study: NCT01142999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aquaphor ointment
Description: One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetaphil cream
Description: One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
Study: NCT03717311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: The intervention will be done on 1 day, time during which, each subject will stay at the CRNH. A breakfast containing the fibers will be given to them, then during 24h a following will be done to get fecal, urinary, plasmatic and expiratory samples. Standardized lunch, dinner and collation will be served during the day.
Study: NCT02040233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAY1067197 (10 mg)
Description: 10 mg BAY1067197 for 7 d treatment once daily as oral application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAY1067197
Description: The dose escalation to the second dose step will proceed only if the previous dose step has shown acceptable safety and tolerability 5 mg / or 10 mg / or 20 mg BAY1067197 for 7 d treatment as oral application.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (10 mg)
Description: 10 mg Placebo for 7 d treatment once daily as oral application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mg / or 10 mg / or 20 mg Placebo for 7 d treatment once daily as oral application
Study: NCT02343614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Study: NCT03251144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to E/C/FTC/TAF daily
Description: If the participant is on an antiretroviral regimen other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)\] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/FTC/TAF) 1 tablet once daily for a period of 12 months.~b) If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months.
Study: NCT02651103

Intervention type: DEVICE
Intervention: NIRS
Description: Cerebral oxygenation monitor which is standard of care for this surgery.
Study: NCT01321177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Treatment
Description: Integrated program of treatments and services delivered by a coordinated team of providers that includes:~* education about schizophrenia and its treatment for the participants and their family members~* medication for symptoms and preventing relapse that uses a computerized decision support system~* strategies for managing the illness and building personal resilience~* help getting back to school or work using a supported employment/education model

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Care
Description: Standard mental health treatments and services offered at the local agency that may include :~* medication for symptoms and preventing relapse~* psychosocial therapy which may include a range of behavioral treatments and supportive services~* Case management
Study: NCT03790137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenfluramine Hydrochloride
Description: Fenfluramine Hydrochloride will be supplied to the treatment group as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive their daily dose of Fenfluramine Hydrochloride in two doses (one in the morning and one in the evening). After a four week baseline, subjects that meet enrollment criteria will enter a titration period. The starting dose will be 0.2 mg/kg/day for the first 14 days. The dose will be increased every 2 weeks as tolerated by 0.2 mg/kg/day, to a maximum dose of 0.7 mg/kg/day, or a total maximum dose of 26 mg/day. The subject will remain on a dose of 0.7 mg/kg/day, 26 mg/day, or maximum tolerated daily dose through the end of the core study period.
Study: NCT06642779

Intervention type: DIAGNOSTIC_TEST
Intervention: UDVA
Description: Monocular and binocular Uncorrected Distance Visual Acuity (UDVA) was evaluated at all visits (preoperative, D1, M1, M3, M6 and M12), using the ETDRS chart.

Intervention type: DIAGNOSTIC_TEST
Intervention: CDVA
Description: Monocular and binocular Corrected Distance Visual Acuity (UDVA) was evaluated at all visits (preoperative, D1, M1, M3, M6 and M12), using the ETDRS chart.

Intervention type: DIAGNOSTIC_TEST
Intervention: CDVA
Description: Monocular and binocular Corrected Distance Visual Acuity (UDVA) was evaluated at all visits (preoperative, D1, M1, M3, M6 and M12), using the ETDRS chart.
Study: NCT03826901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: delgocitinib
Description: Cream for topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: delgocitinib
Description: Cream for topical application
Study: NCT02646800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Injection
Study: NCT00914654

Intervention type: DRUG
Group type: OTHER
Intervention: inhaled formoterol
Description: Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.

Intervention type: DRUG
Group type: OTHER
Intervention: inhaled formoterol
Description: Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.

Intervention type: DRUG
Group type: OTHER
Intervention: inhaled formoterol
Description: Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.
Study: NCT01223755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Patients will be given SRL for one year starting at the oral daily dose of 3 mg, with periodical whole blood level measurements. The daily dose will be adjusted to keep SRL concentration within 5-10 ng/ml. Drug levels will be assessed at day 7 after starting treatment and every two weeks for the first month. Subsequently SRL concentrations will be monitored at monthly intervals (or at least 5 days after drug dose adjustments) until the end of the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Conventional treatment relates usually to the administration of antihypertensive drugs for patients with high blood pressure. Thus, for the present study, no major change in antihypertensive treatment should be introduced throughout the whole study period unless deemed clinically necessary (the reasons of the changes should be, however, clearly explained in the CRF). Only small changes in the doses of the ongoing treatments are recommended in order to maintain the same level of blood pressure control (target systolic/diastolic blood pressure \<130/80 mmHg). This approach is aimed to minimize the confounding effect of any change in concomitant treatments on some efficacy variables (such as urinary protein excretion rate).
Study: NCT01731028

Intervention type: DRUG
Intervention: Somatropin
Description: Somatropin powder and solvent for solution for injection
Study: NCT01236495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spinal morphine 0.3 mg
Description: spinal morphine 0.3 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinal morphine 0.2 mg
Description: spinal morphine 0.2 mg
Study: NCT01780467

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Role of dopamine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Role of dopamine
Study: NCT04237350

Intervention type: BEHAVIORAL
Intervention: Video recording for behaviors
Description: A domenstic apparatus, scenario, and procedure is applied to record all the behavioral phenotypes.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the mobile phone screen. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for about 3 minutes to ensure that behavioral phenotypes could be completely recorded.

Intervention type: BEHAVIORAL
Intervention: Video recording for behaviors
Description: A domenstic apparatus, scenario, and procedure is applied to record all the behavioral phenotypes.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the mobile phone screen. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for about 3 minutes to ensure that behavioral phenotypes could be completely recorded.

Intervention type: BEHAVIORAL
Intervention: Video recording for behaviors
Description: A domenstic apparatus, scenario, and procedure is applied to record all the behavioral phenotypes.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the mobile phone screen. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for about 3 minutes to ensure that behavioral phenotypes could be completely recorded.
Study: NCT02720549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic postconditioning
Description: Remote ischemic postconditioning post group will take a remote ischemic postconditioning with tourniquet in their lower extremity under thigh. The conditioning is 5 minutes of inflation, and 5 minutes of deflation, repeated 3 cycles.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: valvular surgery with bypass
Description: valvular surgery with bypass
Study: NCT01617551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG-monomethyl-L-arginine (L-NMMA)
Description: Acute L-NMMA treatment (4,5 mg/kg loading dose followed by 3 mg/kg sustain infusion for 1 hour)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: NG-monomethyl-L-arginine (L-NMMA)
Description: Acute L-NMMA treatment (4,5 mg/kg loading dose followed by 3 mg/kg sustain infusion for 1 hour)
Study: NCT00413049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/amlodipine 80/5 mg
Description: 1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5 mg
Description: 1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.